The utility of any imaging apparatus in the India preclinical imaging sector is only as good as the contrast agents and molecular probes used with it. There is a rapidly growing demand for advanced, highly specific radiotracers, targeted contrast dyes, and bioluminescent reporters, which enable researchers to visualize specific biological processes at the molecular level.
These agents are...
As of January 2026, the India preclinical imaging market is identifying as a strategic cornerstone of the nation's "Make in India" pharmaceutical push, with the sector projected to surpass a valuation of $210 million this year. The 2026 landscape is defined by the full-scale operationalization of the Anusandhan National Research Foundation (ANRF), which has initiated a specialized ₹750 crore...
A key trend defining the biomedical research domain in India is the growing shift from single-modality to multimodal or hybrid preclinical imaging systems. These advanced platforms, such as Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) and Single-Photon Emission Computed Tomography/Computed Tomography (SPECT/CT), are highly sought after because they combine the strengths of...
The primary engine driving the significant growth of the India Preclinical Imaging Market is the exponential rise in domestic and outsourced drug discovery and development activities originating from both global pharmaceutical companies and emerging Indian biotech firms. India is increasingly positioned as a global Contract Research Organization (CRO) hub due to its cost-effectiveness and large...